Cogent Biosciences, Inc. (COGT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
COGT currently has 171M outstanding shares. with moderate dilution risk from 68.1M authorized shares representing 39.9% potential dilution. The company has significantly diluted shareholders by 58.99% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 170.9M shares outstanding |
170M | 68M |
| Nov 07, 2025 |
10-Q filing | 142.4M shares outstanding |
140M | 97M |
| Aug 05, 2025 |
10-Q filing | 139.7M shares outstanding |
140M | 99M |
| May 06, 2025 |
POS AM filing: This is a Post-Effective Amendment No. 1 deregistering securities from a Registration Statement on Form S-3 as the company has terminated all offerings of securities pursuant to the Registration Statement. |
110M | 130M |
| May 06, 2025 |
10-Q filing | 113.9M shares outstanding |
110M | 130M |
| Feb 25, 2025 |
10-K filing | 113.9M shares outstanding |
110M | 140M |
| Nov 12, 2024 |
10-Q filing | 110.2M shares outstanding |
110M | 140M |
| Aug 06, 2024 |
10-Q filing | 99.2M shares outstanding |
99M | 150M |
| May 07, 2024 |
10-Q filing | 94.8M shares outstanding |
95M | 160M |
| Mar 29, 2024 |
S-3 filing: Cogent Biosciences, Inc. is offering 31,172,997 shares of common stock offered by the Selling Stockholders on a resale basis. |
100M | 150M |
| Feb 26, 2024 |
10-K filing | 103.9M shares outstanding |
100M | 110M |
| Nov 07, 2023 |
10-Q filing | 86.2M shares outstanding |
86M | 130M |
| Aug 08, 2023 |
10-Q filing | 85.5M shares outstanding |
85M | 130M |
| May 09, 2023 |
10-Q filing | 70.7M shares outstanding |
71M | 150M |
| Mar 14, 2023 |
10-K filing | 69.9M shares outstanding |
70M | 150M |
| Nov 14, 2022 |
10-Q filing | 69.6M shares outstanding |
70M | 150M |
| Aug 09, 2022 |
10-Q filing | 65.8M shares outstanding |
66M | 150M |
| May 10, 2022 |
10-Q filing | 45.8M shares outstanding |
46M | 170M |
| May 06, 2022 |
S-3 filing: The company may issue up to an aggregate of $300,000,000 of common stock, preferred stock, debt securities, warrants and/or units, and is offering shares of common stock having an aggregate offering price of up to $75,000,000 in an "at the market offering". |
46M | 170M |
| May 06, 2022 |
POS AM filing: This is a post-effective amendment to deregister all unsold securities from a shelf registration statement and an ATM offering, as the company has terminated all offerings pursuant to the registration statement. |
46M | 170M |
| Mar 15, 2022 |
10-K filing | 45.8M shares outstanding |
46M | 190M |
| Nov 10, 2021 |
10-Q filing | 39.9M shares outstanding |
40M | 200M |
| Aug 16, 2021 |
10-Q filing | 39.8M shares outstanding |
40M | 200M |
| May 12, 2021 |
10-Q filing | 38.4M shares outstanding |
38M | 200M |
| Mar 16, 2021 |
10-K filing | 37.2M shares outstanding |
37M | 200M |
| Feb 09, 2021 |
S-3 filing: The filing is an S-3 form for a potential offering of common stock, preferred stock, debt securities, warrants and/or units up to an aggregate principal amount of $200,000,000. It also includes an at-the-market offering of common stock up to $75,000,000. |
11M | 220M |
| Nov 09, 2020 |
10-Q filing | 11.3M shares outstanding |
11M | 200M |
| Sep 22, 2020 |
S-3 filing: This prospectus relates to the proposed resale or other disposition by the selling shareholders identified herein of (i) 6,235,903 shares of our common stock, (ii) 44,657,000 shares of our Common Stock issuable upon the conversion of 44,657 shares of the Series A Non-Voting Convertible Preferred Stock and (iii) 118,638,000 shares of our Common Stock issuable upon the conversion of 118,638 shares of the Series A Preferred Stock. |
38M | 170M |
| Aug 11, 2020 |
10-Q filing | 38.3M shares outstanding |
38M | 0 |
| May 11, 2020 |
10-Q filing | 31.2M shares outstanding |
31M | 0 |
| Mar 26, 2020 |
10-K filing | 30.6M shares outstanding |
31M | 0 |